Naprosyn (Naproxen) - Drug Information, Research, Clinical Trials, News

Rx drug information, pharmaceutical research, clinical trials, news, and more

Drugs by Name

Drugs by Condition

Drugs by Category

Alerts

Naprosyn Rx

FDA Alerts Summary Description Indications and Dosage Warnings and Precautions Side Effects and Adverse Reactions Drug Interactions, Overdosage and Contraindications Clinical Pharmacology Other Rx Information Active Ingredients Adverse Event Reports User Ratings / Reviews

Naprosyn News

News in Media Published Studies Curr't Clinical Trials

-- advertisement --

Cardiovascular Risk

NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS).
Naproxen as NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).

Gastrointestinal Risk

NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).

NAPROSYN SUMMARY

EC-NAPROSYN^® (naproxen delayed-release tablets)
NAPROSYN^® (naproxen tablets)
ANAPROX^®/ANAPROX^® DS (naproxen sodium tablets)
NAPROSYN^® (naproxen suspension)

Naproxen is a member of the arylacetic acid group of nonsteroidal anti-inflammatory drugs.

Naproxen as NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension are indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and juvenile arthritis.

Naproxen as NAPROSYN Suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight.

Naproxen as NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension are also indicated for the treatment of tendonitis, bursitis, acute gout, and for the management of pain and primary dysmenorrhea. EC-NAPROSYN is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).